Skip to main content
Karolinska Development logo

Karolinska Development — Investor Relations & Filings

Ticker · KDEV ISIN · SE0002190926 LEI · 54930011ZA52NKO5W681 ST Financial and insurance activities
Open in API
Filings indexed 761 across all filing types
Latest filing 2017-10-04 Capital/Financing Update
Country SE Sweden
Listing ST KDEV

About Karolinska Development

https://www.karolinskadevelopment.com/en

Karolinska Development is an investment company specializing in the life sciences sector. It identifies, finances, and supports the creation and growth of companies developing innovative medical technologies and pharmaceuticals. The firm manages a diversified portfolio of biotechnology and medtech ventures, often originating from academic research, with the goal of developing ground-breaking treatments for severe diseases. Karolinska Development leverages its team's expertise in research, development, and commercialization to guide its portfolio companies, providing both capital and strategic support to advance innovations toward the market.

Recent filings

Filing Released Lang Actions
Karolinska Developments portföljbolag Umecrine Cognition säkrar finansiering för klinisk utveckling av läkemedelskandidaten GR3027 mot sömnstörningar
Capital/Financing Update Classification · 1% confidence The document announces that a portfolio company of Karolinska Development, Umecrine Cognition, has secured financing (a new share issue of 20 mkr) specifically to fund the clinical development (Phase 2a study) of a drug candidate (GR3027). The core subject is a capital raising event intended to finance future operations and development, which directly aligns with the definition of 'Capital/Financing Update'. The document is a press release announcing this specific financial activity, not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS).
2017-10-04 Swedish
Karolinska Development's portfolio company BioArctic intends to list on Nasdaq Stockholm
Capital/Financing Update Classification · 1% confidence The document is a press release from Karolinska Development announcing that its portfolio company, BioArctic, intends to list its shares on Nasdaq Stockholm. This announcement details a significant corporate action related to fundraising, capital structure, and potential future financing/valuation changes. This fits best under the 'Capital/Financing Update' category, as it is a direct announcement regarding a planned equity offering/listing, which is a form of capital activity. It is not a full 10-K, an earnings release (ER), or a formal proxy statement (DEF 14A). Given the nature of the announcement (intent to list/IPO preparation), CAP is the most appropriate code.
2017-09-13 English
Karolinska Developments portföljbolag BioArctic avser genomföra notering på Nasdaq Stockholm
Capital/Financing Update Classification · 1% confidence The document is an announcement from Karolinska Development AB regarding its portfolio company, BioArctic AB, intending to list its shares on Nasdaq Stockholm. This announcement details a significant corporate financing/capital structure event (an Initial Public Offering or listing preparation) involving the company's equity. This aligns directly with the definition of 'Capital/Financing Update' (CAP). Although it relates to a potential share issue, the primary focus is the financing activity (the listing) rather than just the mechanics of a share buyback (POS) or a general share change (SHA). It is not a formal regulatory filing like a 10-K or an Earnings Release (ER).
2017-09-13 Swedish
Ändring av antal aktier och röster i Karolinska Development
Share Issue/Capital Change Classification · 1% confidence The document explicitly states an 'Ändring av antal aktier och röster' (Change in the number of shares and votes) due to conversion of convertible loans and allocation from an incentive program. It provides the new total number of shares and votes as of the last trading day of the month. This type of announcement, detailing changes in the total share count, directly relates to the company's capital structure. This fits best under 'Capital/Financing Update' (CAP), as it is a direct consequence of financing activities (convertible loan conversion) and results in a change to the share count. It is not a general regulatory filing (RNS) because it is highly specific to capital structure changes, nor is it a share repurchase (POS) as it results from debt conversion and incentive vesting.
2017-08-31 Swedish
Change of Number of Shares and Votes in Karolinska Development
Share Issue/Capital Change Classification · 1% confidence The document explicitly announces a change in the total number of outstanding shares and votes due to the conversion of convertible loans and allotment of shares from an incentive program. This directly relates to changes in the company's capital structure. The filing category 'Share Issue/Capital Change' (SHA) is the most appropriate fit for announcements detailing alterations to the number of shares outstanding, which is the core subject of this text. It is not an earnings release, a dividend notice, or a general regulatory filing fallback.
2017-08-31 English
Interim / Quarterly Report 2017
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive financial report for Karolinska Development AB covering the second quarter of 2017. It includes detailed financial data (income statement highlights, portfolio valuation, cash flow, and equity), management's discussion and analysis (MDA) of business trends, operational updates, and future outlook. It is not a mere announcement (RPA) or a simple earnings release (ER) as it provides substantive financial analysis and management commentary. Therefore, it is classified as an Interim/Quarterly Report. Q2 2017
2017-08-29 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.